Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Can’t-Miss Health-Care Events This Week: GlaxoSmithKline plc (ADR)(GSK), Theravance Inc (THRX)

Page 1 of 2

With no PDUFA decisions on the plate this week, we’ll instead turn our attention to two important FDA panel meetings and two earnings reports that simply can’t be missed.

On Monday, Depomed Inc (NASDAQ:DEPO) is expected to go before the FDA panel with its menopausal hot-flash drug, Serada. As’s Aafia Chaudrey noted in early February, DepoMed’s first two Breeze trials were largely unsuccessful, with neither hitting their primary endpoints and dropout rates running very high. The Breeze-3 trial, from which this new drug application originates, demonstrates a reduction and frequency of hot flashes relative to placebo but still showed a higher number of patients dropping out of the trial because of adverse events than the placebo (16.7% to 11.5%). It’s really difficult to tell how the FDA’s panel will perceive this data at the moment.

GlaxoSmithKline plc (ADR) (NYSE:GSK)Later in the week, on Thursday, GlaxoSmithKline plc (ADR)(NYSE:GSK) and Theravance Inc (NASDAQ:THRX) will face the FDA panel with their long-term COPD solution, Breo Ellipta. The inhaled drug combines a long-acting beta agonist with a once daily inhaled corticosteroid to provider 24-hour relief to COPD suffers. In two mid-stage trials spanning 1,620 patients, the first trial demonstrated statistical significance at all three dosing levels, while the second demonstrated statistical significance at the lowest and mid-tiered dosing level. Both studies exhibited a reduction in COPD exacerbations, though not all figures were numerically significant. In short, GlaxoSmithKline plc (ADR)(NYSE:GSK) and Theravance Inc (NASDAQ:THRX) could have a blockbuster on their hands, as long as the FDA panel feels the results show a marked improvement over existing treatments. Thursday is a key day for these two companies!

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!